Brought to you by 
Amryt to sell Aegerion's Lojuxta in certain European and Middle Eastern countries
06 Dec 2016
Executive Summary
Novelion Therapeutics Inc.'s subsidiary Aegerion Pharmaceuticals Inc. licensed rare disease-focused Amryt Pharma PLC exclusive rights to promote and distribute Lojuxta (lomitapide) capsules in the European Economic Area, Switzerland, Turkey, and certain Middle Eastern and North African countries including Israel.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amryt to sell Aegerion's Lojuxta in certain European and Middle Eastern countries
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice